Rinucumab
Monoclonal antibody
Type?
SourceHuman
Targetplatelet-derived growth factor receptor beta
Clinical data
Other namesREGN2176
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6472H9974N1710O2022S38
Molar mass145309.21 g·mol−1

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.[1][2]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

  1. ^ "Rinucumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. ^ Hussain RM, Ciulla TA (September 2017). "Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration". Expert Opinion on Emerging Drugs. 22 (3): 235–246. doi:10.1080/14728214.2017.1362390. PMID 28756707. S2CID 3505145.
Categories